## Chi-Chuan Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4596477/publications.pdf

Version: 2024-02-01

686830 580395 37 671 13 25 citations g-index h-index papers 39 39 39 1088 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Amantadine treatment and delayed onset of levodopaâ€induced dyskinesia in patients with early Parkinson's disease. European Journal of Neurology, 2022, 29, 1044-1055.	1.7	10
2	Postâ€Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e022849.	1.6	7
3	Continuity and Completeness of Electronic Health Record Data for Patients Treated With Oral Hypoglycemic Agents: Findings From Healthcare Delivery Systems in Taiwan. Frontiers in Pharmacology, 2022, 13, 845949.	1.6	2
4	Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan. Pharmacoepidemiology and Drug Safety, 2021, 30, 97-101.	0.9	11
5	Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams. Journal of Antimicrobial Chemotherapy, 2021, 76, 499-506.	1.3	7
6	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. Current Medical Research and Opinion, 2021, 37, 535-542.	0.9	8
7	Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States. Scientific Reports, 2021, 11, 11025.	1.6	36
8	Effect of <scp>ICDâ€9â€CM</scp> to <scp>ICDâ€10â€CM</scp> coding system transition on identification of common conditions: An interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 1653-1674.	0.9	12
9	Comparison of Bleeding Risk Between Colistin–Tigecycline and Colistin–Carbapenem Treatment Regimens: A Retrospective Cohort Study. Infection and Drug Resistance, 2021, Volume 14, 4949-4955.	1.1	2
10	Costâ€benefit of reimbursement for pharmaceutical care in Taiwan. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 604-611.	0.5	1
11	Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Anti-inflammatory Drugs: A Nested Case-Control Study. Annals of Pharmacotherapy, 2020, 55, 106002802098041.	0.9	9
12	<p>Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study</p> . Infection and Drug Resistance, 2019, Volume 12, 2531-2541.	1.1	30
13	A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin. JMIR Medical Informatics, 2019, 7, e13329.	1.3	1
14	Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study. Scientific Reports, 2018, 8, 3451.	1.6	23
15	Reimbursement changes and drug switching: are severe patients more affected?. Journal of Health Services Research and Policy, 2017, 22, 76-82.	0.8	3
16	Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan. International Journal for Quality in Health Care, 2017, 29, 817-825.	0.9	14
17	Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Kidney and Blood Pressure Research, 2017, 42, 358-368.	0.9	35
18	Antidepressants and Valvular Heart Disease. Medicine (United States), 2016, 95, e3172.	0.4	5

#	Article	IF	CITATIONS
19	The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis. Journal of Women's Health, 2016, 25, 738-746.	1.5	2
20	Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia. Medicine (United States), 2016, 95, e2763.	0.4	5
21	Fluoroquinolones versus $\hat{l}^2$ -Lactam $\hat{l}^2$ -Lactamase Inhibitors in Outpatients with Chronic Obstructive Pulmonary Disease and Pneumonia: A Nationwide Population-Based Study. PLoS ONE, 2015, 10, e0136232.	1.1	5
22	Patterns of Pharmacological Treatment for Osteoporosis Among Patients Qualified for Pharmacotherapy According to the National Osteoporosis Foundation Guidelines. Annals of Pharmacotherapy, 2015, 49, 995-1003.	0.9	6
23	Alternative Therapies as a Substitute for Costly Prescription Medications: Results from the 2011 National Health Interview Survey. Clinical Therapeutics, 2015, 37, 1022-1030.	1.1	6
24	Trend and Pattern of Herb and Supplement Use in the United States: Results from the 2002, 2007, and 2012 National Health Interview Surveys. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-7.	0.5	56
25	Treatment Patterns, Complications, and Disease Relapse in a Real-world Population of Patients with Moderate-to-severe Ulcerative Colitis Initiating Immunomodulator Therapy. Inflammatory Bowel Diseases, 2014, 20, 1361-1367.	0.9	8
26	Trends in energy and macronutrient intakes by weight status over four decades. Public Health Nutrition, 2014, 17, 256-265.	1.1	24
27	Examining the Relationship Between Adjunctive Psychotherapy Use and Antipsychotic Persistence and Hospitalization. Administration and Policy in Mental Health and Mental Health Services Research, 2014, 41, 598-607.	1.2	2
28	Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder. Applied Health Economics and Health Policy, 2014, 12, 335-346.	1.0	16
29	Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine, 2013, 31, 3370-3388.	1.7	19
30	National trends of psychotropic medication use among patients diagnosed with anxiety disorders: Results from Medical Expenditure Panel Survey 2004–2009. Journal of Anxiety Disorders, 2013, 27, 163-170.	1.5	23
31	Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey. Research in Social and Administrative Pharmacy, 2013, 9, 263-275.	1.5	17
32	The prevalence of herb and dietary supplement use among children and adolescents in the United States: Results from the 2007 National Health Interview Survey. Complementary Therapies in Medicine, 2013, 21, 358-363.	1.3	28
33	Impact of Monthly Prescription Cap on Medication Persistence Among Patients with Hypertension, Hyperlipidemia, or Diabetes. Journal of Managed Care Pharmacy, 2013, 19, 258-268.	2.2	3
34	Changes in Herb and Dietary Supplement Use in the US Adult Population: A Comparison of the 2002 and 2007 National Health Interview Surveys. Clinical Therapeutics, 2011, 33, 1749-1758.	1.1	136
35	Coverage of Atypical Antipsychotics Among Medicare Drug Plans in the State of Washington. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 316-321.	0.6	2
36	Patient Disclosure about Herb and Supplement Use among Adults in the US. Evidence-based Complementary and Alternative Medicine, 2008, 5, 451-456.	0.5	93

#	Article	IF	CITATIONS
37	Coverage of Atypical Antipsychotics Among Medicare Drug Plans in the State of Washington for Fiscal Year 2007. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 313-317.	0.6	3